Form 4 for CRL Charles River Laboratories
Accepted 2022-06-01 00:00:00 ET · period of report 2022-05-27 · accession 0001127602-22-016215 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-06-01 | 2022-05-29 | CRL | FOSTER JAMES C | COB, Pres, CEO, Dir | F - Tax | $244.41 | -1,311 | 213.7K | -0.6% | -$320.4K |
| D | 2022-06-01 | 2022-05-27 | CRL | FOSTER JAMES C | COB, Pres, CEO, Dir | A - Grant | $244.41 | +24.0K | 24.0K | New | +$5.88M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-29 | F | D | 1,311 | $244.41 | 213,711 | D | — | — | |
| 2 | Derivative | Stock Options (Right to Buy) | 2022-05-27 | A | A | 24,042 | $244.41 | 24,042 | D | $244.41 · 2023-05-27 to 2032-05-27 | 24,042 Common Stock | (F1) Stock Options vest as follows: 6,010 on May 27, 2023, 6,011 on May 27, 2024, 6,010 on May 27, 2025 and 6,011 on May 27, 2026. |